Anti-cancer Therapies in High Grade Gliomas
Cristiana Pistol Tanase, Ana-Maria Enciu, Simona Mihai, Ana Iulia Neagu, Bogdan Calenic and Maria Linda Cruceru
Pages 246-260 (15)
High grade gliomas represent one of the most aggressive and treatment-resistant types of human cancer, with
only 1–2 years median survival rate for patients with grade IV glioma. The treatment of glioblastoma is a considerable
therapeutic challenge; combination therapy targeting multiple pathways is becoming a fast growing area of research. This
review offers an up-to-date perspective of the literature about current molecular therapy targets in high grade glioma, that
include angiogenic signals, tyrosine kinase receptors, nodal signaling proteins and cancer stem cells related approaches.
Simultaneous identification of proteomic signatures could provide biomarker panels for diagnostic and personalized
treatment of different subsets of glioblastoma. Personalized medicine is starting to gain importance in clinical care, already
having recorded a series of successes in several types of cancer; nonetheless, in brain tumors it is still at an early
Antiangiogenic therapy, cancer stem cells, glioma, microRNA, personalized medicine, PI-3K.
Victor Babes National Institute of Pathology, Dept. of Biochemistry-Proteomics, no 99-101 Splaiul Independentei, 050096 sect 5 Bucharest, Romania.